Combining Siltuximab with Melphalan for Multiple Myeloma Patients Undergoing Stem Cell Transplant
Phase II Randomized Trial of Population PK Dosed Melphalan With Interleukin-6 Blockade With Siltuximab Vesrus BSA Based Melphalan in Patients With Multiple Myeloma Over Age 60 Undergoing Autologous Stem Cell Transplantation
PHASE2 · Memorial Sloan Kettering Cancer Center · NCT06679829
This study is testing if combining a new drug called siltuximab with a standard treatment for multiple myeloma can help patients feel better after a stem cell transplant.
Quick facts
| Phase | PHASE2 |
|---|---|
| Study type | Interventional |
| Enrollment | 215 (estimated) |
| Ages | 60 Years and up |
| Sex | All |
| Sponsor | Memorial Sloan Kettering Cancer Center (other) |
| Drugs / interventions | siltuximab |
| Locations | 7 sites (Basking Ridge, New Jersey and 6 other locations) |
| Trial ID | NCT06679829 on ClinicalTrials.gov |
What this trial studies
This study investigates the effectiveness of siltuximab combined with population pharmacokinetic-dosed melphalan compared to the standard body surface area-dosed melphalan in patients with multiple myeloma undergoing autologous stem cell transplantation. The trial aims to assess whether this combination can improve outcomes and reduce symptoms post-transplant. Additionally, the safety profile of siltuximab will be evaluated. A run-in phase will involve a small group of patients receiving siltuximab before and after the stem cell infusion.
Who should consider this trial
Good fit: Ideal candidates are individuals aged 60 and older with symptomatic multiple myeloma who are preparing for autologous stem cell transplantation.
Not a fit: Patients with severe comorbidities or those not meeting the eligibility criteria may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could enhance treatment efficacy and symptom management for multiple myeloma patients undergoing stem cell transplantation.
How similar studies have performed: Previous studies have shown promise in using targeted therapies like siltuximab in combination with traditional treatments for multiple myeloma, suggesting potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Histologically-confirmed symptomatic multiple myeloma undergoing autologous HCT with plan off study for melphalan 140 or 200 mg/m2 undergoing HCT within 12 months of diagnosis. * At least 60 years of age * Have at least 3 million x 10\^6 CD34+ cells/kg to be infused * KPS performance status \>60% or ECOG Performance Status score of 0-2 Within 6 weeks prior to enrollment: * Diffusion capacity \>45% (adjusted for hemoglobin) as predicted by pulmonary function testing. * LVEF \>45% by MUGA or rest ECHO * Clinical laboratory values meeting the following criteria * Platelet count ≥ 20 x 10\^9/L * ALT and AST ≤ 2.5 x ULN o Total bilirubin ≤ 2.5 x ULN; except if the elevation is due to Gilbert's syndrome * Calculated creatinine clearance \> 40 mL/min * Before enrollment, all women are expected to be not of childbearing potential as they will be age 60+. * A man who is sexually active with a woman of childbearing potential and has not had a vasectomy must agree to use a barrier method of birth control eg, either condom with spermicidal foam/gel/film/cream/suppository or partner with occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository, and all men must also not donate sperm during the study and for 3 months after receiving the last dose of study drug Exclusion Criteria: * Prior exposure to agents targeting IL-6 or the IL-6 receptor * Other malignancy within the past 2 years, except for the following if treated and not active: basal cell or nonmetastatic squamous cell carcinoma of the skin, cervical carcinoma in situ or International Federation of Gynecology and Obstetrics (FIGO) Stage 1 carcinoma of the cervix. Prostate cancer under observation may be enrolled after discussion with the MSK Principal Investigator. * Concurrent medical condition or disease (eg, autoimmune disease, active systemic Infection) that is likely to interfere with study procedures or results, or that in the opinion of the investigator would constitute a hazard for participating in the study * Ischemic heart disease requiring intervention in the prior 3 months or uncontrolled heart failure or an uncontrolled arrhythmiaQTc is \>460ms by Fridericia. If they have a right or left bundle branch block or intraventricular conduction delay then exclusion will be for \>500ms by Friderica. * Vaccination with live attenuated vaccines within 4 weeks of first study agent administration * Clinically significant infection, including known HIV or hepatitis C infection, or known hepatitis B (Hep B) surface antigen positivity. Patients with Hep B Core positivity can be enrolled if the Hep B PCR is negative, and they are on antiviral suppression. Patients with Hepatitis C Ab positive who are PCR negative and have completed Hepatitis C treatment can be enrolled. HIV with negative viral load on HAART can be enrolled. * Received an investigational drug (including investigational vaccines) or used an invasive investigational medical device within 14 days or 5 half lives before enrollment or is currently enrolled in the treatment stage of an investigational study * Had hospitalization for infection or major surgery (eg, requiring general anesthesia) within 2 weeks before enrollment or have not fully recovered from surgery. Note: subjects with surgical procedures conducted under local anesthesia may participate * A man who plans to father a child while enrolled in this study or within 3 months after the last dose of study agent.
Where this trial is running
Basking Ridge, New Jersey and 6 other locations
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) — Basking Ridge, New Jersey, United States (RECRUITING)
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) — Middletown, New Jersey, United States (RECRUITING)
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) — Montvale, New Jersey, United States (RECRUITING)
- Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities) — Commack, New York, United States (RECRUITING)
- Memorial Sloan Kettering Westchester (Limited Protocol Activities) — Harrison, New York, United States (RECRUITING)
- Memorial Sloan Kettering Cancer Center (All protocol activities) — New York, New York, United States (RECRUITING)
- Memorial Sloan Kettering Nassau (Limited Protocol Activities) — Uniondale, New York, United States (RECRUITING)
Study contacts
- Principal investigator: Gunjan Shah, MD, MS — Memorial Sloan Kettering Cancer Center
- Study coordinator: Gunjan Shah, MD
- Email: ABMTTrials@mskcc.org
- Phone: 646-608-3734
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Multiple Myeloma, Melphalan, Interleukin-6 Blockade with Siltuximab, Autologous Stem Cell Transplantation